Letrozole, 100mg (1mg/100tabs)
$89.95 If paid in BTC $71.96
Letrozole, 100mg 1mg
Total amount of active ingredient: 100mg
•USA: $6.95 (3-7 business days)
•CA: $10.50 (3-7 business days)
•International: $39 (7-14 business days)
If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.
Quantity: 100 tabs
Packaging: Capsulated and in Mylar Bags
Label: 7.5cm x 2.8cm
Product made and housed in the USA and Europe.
Letrozole is an aromatase inhibitor which is used in the treatment of hormonally-responsive breast cancer after surgery. It is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor-positive or has an unknown receptor status in postmenopausal women.
Comparison with tamoxifen
Tamoxifen is also used to treat hormonally-responsive breast cancer, but it does so by interfering with the estrogen receptor. However, letrozole is effective only in post-menopausal women, in whom estrogen is produced predominantly in peripheral tissues (i.e. in adipose tissue, like that of the breast) and a number of sites in the brain. In pre-menopausal women, the main source of estrogen is from the ovaries, not the peripheral tissues, and letrozole is ineffective.
In the BIG 1–98 Study, of post-menopausal women with hormonally-responsive breast cancer, letrozole reduced the recurrence of cancer but did not change survival rate, compared to tamoxifen.
Letrozole is contraindicated in women having a pre-menopausal hormonal status, during pregnancy and lactation.
Letrozole inhibits the liver enzyme CYP2A6, and to a lesser extent CYP2C19, in vitro, but no relevant interactions with drugs like cimetidine and warfarin have been observed.
All of our products are lab tested and the results are periodically published on the website.
Also known as: 4,4′-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile), CGS 20267, Femara